Skip to main content

Table 4 Multivariable analysis of factors associated with a CDT of BMA in the subpopulation with no hematological malignancy or cancer known on admission (N = 160)

From: Contribution to diagnosis and treatment of bone marrow aspirate results in critically ill patients undergoing bone marrow aspiration: a retrospective study of 193 consecutive patients

Variable Odds ratio 95% confidence interval P value
First model
 Non-malignant hematological abnormality known on admission 7.75 [1.77–34.02] 0.007
 Indication of BMA excluding isolated TPa,b 3.32 [1.16–9.51] 0.025
 SOFA scorec 1.19 [1.06–1.34] 0.003
 Pre-BMA HScorec,d 1.03 [1.01–1.04] < 0.001
Second model
 Non-malignant hematological abnormality known on admission 6.76 [1.51–30.38] 0.013
 Indication of BMA excluding isolated TPa,b 3.82 [1.19–12.24] 0.024
 SOFA—platelet-count SOFA subscorec 1.19 [1.04–1.35] 0.009
 Pre-BMA HScorec,d 1.03 [1.01–1.04] < 0.001
 Platelet count SOFA subscore 0 versus other groups 2.14 [0.60–7.62] 0.239
  1. BMA bone marrow aspiration, CDT contribution to diagnosis and/or treatment, Hscore reactive hemophagocytic syndrome diagnostic score, SOFA sequential organ failure assessment, TP thrombocytopenia
  2. aThrombocytopenia may be present or absent in these patients
  3. bIsolated thrombocytopenia, i.e., thrombocytopenia was the only indication for BMA
  4. cPer point
  5. dCalculated with no points assigned for the cytological variable